30-Jan-2026
Harrow to Present at Two Investor Conferences in December
Globe Newswire (Mon, 24-Nov 7:00 AM ET)
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Globe Newswire (Tue, 18-Nov 7:00 AM ET)
Market Chameleon (Tue, 11-Nov 5:35 AM ET)
Harrow Delivers 45% Revenue Growth, Major Access Wins, and Strong Adjusted EBITDA in Q3 2025
Market Chameleon (Tue, 11-Nov 4:14 AM ET)
Harrow Announces Third Quarter 2025 Financial Results
Globe Newswire (Mon, 10-Nov 4:09 PM ET)
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Harrow trades on the NASDAQ stock market under the symbol HROW.
As of January 30, 2026, HROW stock price declined to $40.94 with 386,108 million shares trading.
HROW has a beta of 1.94, meaning it tends to be more sensitive to market movements. HROW has a correlation of 0.30 to the broad based SPY ETF.
HROW has a market cap of $1.51 billion. This is considered a Small Cap stock.
Last quarter Harrow reported $72 million in Revenue and $.33 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.11.
In the last 3 years, HROW traded as high as $59.23 and as low as $7.60.
The top ETF exchange traded funds that HROW belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
HROW has outperformed the market in the last year with a return of +29.2%, while the SPY ETF gained +15.6%. In the last 3 month period, HROW beat the market returning +9.0%, while SPY returned +2.1%. However, in the most recent 2 weeks HROW has underperformed the stock market by returning -14.5%, while SPY returned 0.0%.
HROW support price is $40.25 and resistance is $43.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HROW shares will trade within this expected range on the day.